5 research outputs found
A Comparative Research on Municipal Voluntary Tasks of Three Hungarian and Slovenian Municipalities
Endophytic fungi from the roots of horseradish (Armoracia rusticana) and their interactions with the defensive metabolites of the glucosinolate myrosinase – isothiocyanate system
K
Efficient biotransformation of non-steroid anti-inflammatory drugs by endophytic and epiphytic fungi from dried leaves of a medicinal plant, Plantago lanceolata L.
Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial
Background: Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials.
Patients and Methods: The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate >= 25 mL/min/1.73 m(2) and albuminuria (urinary albumin-to-creatinine ratio >= 30 to <= 5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level alpha = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure.
Conclusions: FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen.
Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049
Genetic Alterations in Hungarian Patients with Papillary Thyroid Cancer
The incidence of thyroid cancers is increasing worldwide. Some
somatic oncogene mutations (BRAF, NRAS, HRAS, KRAS) as well as gene
translocations (RET/PTC, PAX8/PPAR-gamma) have been associated with
the development of thyroid cancer. In our study, we analyzed these
genetic alterations in 394 thyroid tissue samples (197 papillary
carcinomas and 197 healthy). The somatic mutations and
translocations were detected by Light Cycler melting method and
Real-Time Polymerase Chain Reaction techniques, respectively. In
tumorous samples, 86 BRAF (44.2 %), 5 NRAS (3.1 %), 2 HRAS (1.0 %)
and 1 KRAS (0.5 %) mutations were found, as well as 9 RET/PTC1 (4.6
%) and 1 RET/PTC3 (0.5 %) translocations. No genetic alteration was
seen in the non tumorous control thyroid tissues. No correlation
was detected between the genetic variants and the pathological
subtypes of papillary cancer as well as the severity of the
disease. Our results are only partly concordant with the data found
in the literature